Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca and Daiichi Sankyo's new ...

Data from trials wowed ESMO in September 2020, where Trodelvy was shown to significantly extend overall survival (OS) and improved overall response rate (ORR) and clinical benefit rate (CBR ...

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

“ESMO 2022 had really outstanding sessions for ... as well as fallopian tube and primary peritoneal cancer. In 2020, there were over 55,000 new diagnoses of ovarian cancer in China.

Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enrich ...

Our blood-based colon cancer screening data presented at ESMO in September demonstrated ... on the cohorts of new ordering physicians from 2020 and beyond at half the rate that we’re calling ...

The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed. Led by a Singapore clinician-investigator, the global, international, ...

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell therapy.

CureVac N.V. ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that new and updated data ...

Operator Good day, ladies and gentlemen, and welcome to Exelixis' third quarter 2024 financial results conference call. My ...